Molekule’s Specific U.S. Capabilities
Molekule is headquartered in Miami, FL and has strategically positioned offices in New York City and New Jersey.
Molekule consultants solely conduct ethical, elicitation-style competitive intelligence primary research - neither honorarium, nor compensation are rendered to respondents. All conversations are non-transactional.
The U.S.-market and U.S.-headquartered biopharma represent ~50% of Molekule’s total annual workload.
Molekule annually conducts more than 60 U.S.-based primary research projects and 15+ competitive simulations - the team also attends 50+ U.S. congresses across therapy areas and subject matters.
Our U.S.-team understands the nuances of U.S.-market pricing & market access, regulatory, go-to-market strategy, field force sizing and structure and generics & biosimilars - we are therefore, well-positioned to support.
Molekule’s Specific European Capabilities
Molekule established its European HQ in 2017 to specifically serve the European market.
Molekule has conducted 27 projects in the last 12 months in Europe covering EU5, Nordic countries, Eastern European countries, Switzerland, and others.
Molekule consultants are “fluent” in 17 languages and therefore can conduct most primary CI interviews in the native language of the person interviewed.
Molekule has in-house consultants on the ground in many of the major European countries.
Today, 40% of Molekule’s work is for European companies and/or focus is the European market.
Molekule Consulting's LATAM Engagement Experience
Molekule maintains a highly granularized and dialed-in perspective regarding the LATAM biopharmaceutical market - commercial/marketing, regulatory/technical, clinical/medical and manufacturing/supply chain logistics - in support of our client partners.
Understanding the regulatory, manufacturing and supply chain logistics, clinical and commercial dynamics of LATAM-based biosimilars players for three (3) key oncology biologic assets in key markets (Argentina, Brazil, Bolivia, Chile, Cuba, Mexico, Venezuela)
Targeted due diligence and threat assessment of Brazil-based local, regional and extra-regional (i.e.- MNC biopharmaceutical companies with a presence in Brazil) biopharmaceutical players and their intentions to establish distribution hubs/nodes in the Brazil market
Due diligence assessment: a Brazil-based Biotech, a Mexico Based Biotech, and a Russia-based Biotech as potential LATAM alliance partners and/or M&A targets
Elucidation of local-MNC partnerships among LATAM-based biopharmaceutical players and potential and/or realized MNC pharmacos
Competitive intelligence assessment of the LATAM generics and innovator small molecule pharmaceutical market in Argentina, Brazil, Cuba and Mexico
Regulatory assessment of ANVISA’s “risk tolerance appetite” for MNC biopharmaceutical companies’ regulatory dossiers and forecasting of the subsequent pricing & reimbursement of these assets, forward-looking
Targeted assessment: Fiocruz (Bio-Manguinhos) and its vaccines and biosimilars capabilities for the LATAM market
Our Deep and Significant Experience In Asia-Pacific (“A-P”) and Asean Markets
A Select View of Molekule’s A-P AND ASEAN FOCUSED Engagements
Determining the competitive threat of a China-based biopharmaceutical player with respect to its anti VEGF ophthalmology asset; a focused assessment of ex-China opportunity, strategic intent and tactical implementation
Focused assessment of a mid-sized Japan-based pharmaceutical player to determine ex-Japan strategic intentions with respect to a high potential developmental biosimilar asset
Targeted assessment of ASEAN local and regional diabetes players: how will diabetes competitors leverage a portfolio of both injectable and oral antidiabetic agents to drive an extra-regional Asia-Pacific strategy.
Deep dive assessment of emerging Asia-Pacific markets – Thailand, Malaysia, China, S. Korea, Vietnam and Cambodia – MNC biopharmas’ strategic intent, tactical implementation and overt mid-range strategic plans
Comprehensive assessment of emerging Korea-based biosimilars competitors: determining developmental portfolio strategies & priorities, partnerships & tie-ups and long-range commercialization plans
Understanding the emerging novel anti-viral market in key Tier II/Tier III ASEAN and Asia-Pacific markets
Comprehensive landscape monitoring of diosgenin and androstenedione manufacturing, distribution, wholesale, trade and resale in Asia-Pacific markets
